For instance, the tissue plasminogen activator (tPA), which is currently the only therapeutic agent approved to treat patients with acute ischemic stroke, manifests clinical benefits within 4.5 h of stroke onset (Kim, 2019). The gene discussed is PLAT; the disease is stroke disorder.